Navigation Links
More Than 300 New Medicines Being Developed for Mental Illnesses
Date:7/24/2008

NEW ORLEANS, July 24 /PRNewswire-USNewswire/ -- There are a record 301 new medicines being developed for mental illnesses, according to a new report released here today during a briefing that focused on the devastating effects that mental illnesses have on patients, their families, and society. Nationwide, mental illness affects nearly 60 million American adults. The briefing, led by the Pharmaceutical Research and Manufacturers of America (PhRMA), featured Emmy Award-winning actor Joey Pantoliano -- well known for his role in The Sopranos -- who suffers from depression.

In Louisiana, rates of post-traumatic stress disorder and suicide have increased since hurricanes Katrina and Rita, according to the National Institute on Drug Abuse. Mental disorders after a natural disaster usually decrease with time, with about 50 percent of post-traumatic mental disorders resolved within a year of the disaster, notes a recent Harvard University study. However, in the case of Hurricane Katrina, the researchers found the contrary: Anxiety or mood disorder has been increasing by 30 percent and more.

"We are releasing this report in Louisiana in view of the upcoming third anniversary of Hurricane Katrina and the state's continuing need for assistance in treating mental illness," said PhRMA Senior Vice President Ken Johnson. "The medicines being developed treat a range of conditions, from depression to anxiety, and from schizophrenia to dependence on alcohol and drugs. These medicines are either in clinical trials or awaiting review by the U.S. Food and Drug Administration, and they will help patients live longer, happier, and healthier lives. It's important for patients and healthcare providers to know that research into mental illness remains a top priority."

Many of these diseases, such as depression, were once misunderstood causes of shame and fear. Fortunately, today many are highly treatable conditions.

Unfortunately, despite the tremendous progress, mental illness continues to exact a heavy human and economic toll in this country. According to the National Institute of Mental Health, the total cost (direct and indirect) of treating mental illnesses in the United States is $205 billion a year.

Included in the report's new medicines in the research pipeline are: 66 medicines for depression, which affects nearly 21 million Americans; 26 medicines for addictive disorders, including dependence on alcohol, tobacco or illicit drugs; 54 medicines for anxiety disorders, which affect more than 40 million adults ages 18 and older; 89 for dementias, including Alzheimer's disease, which affects more than 5 million Americans; and 45 for schizophrenia, which strikes some 2.4 million adults each year.

"Patients and healthcare providers need to know that there are many new, potential options out there that could allow them a better quality of life," said Pantoliano. "Instead of suffering in silence and isolating themselves, as I did for many years, I encourage everyone with a mental illness -- or who thinks they may have a mental illness -- to find out what the options are and seek treatment. People who are suffering need to know that there is hope."

Joey Pantoliano is one of the best-known character actors in Hollywood, appearing in more than 100 movies and television shows. But he is probably best known for his critically acclaimed and Emmy award-winning performance as psychopathic mobster Ralphie Cifaretto on The Sopranos. His lengthy movie credits include Risky Business, The Matrix, The Fugitive, U.S. Marshals, Bad Boys, Empire of the Sun, Running Scared and The Goonies. In his most recent film, Canvas, Pantoliano plays a husband trying to hold his family together while his wife, portrayed by Oscar-winning actress Marcia Gay Harden, battles schizophrenia. Making the film helped Pantoliano come to terms with his own depression, a condition he revealed he has been suffering from for more than a decade. Rather than hide his struggle from the public, Pantoliano has chosen to speak out about his disease, and founded the organization "No Kidding, Me Too!" (http://www.nkm2.org) to help remove the isolation and stigma that often surrounds mental illness.

Johnson stressed that while researchers are making exciting progress in the search for new cures and treatments for mental health disorders, these efforts are wasted if the medicines that are developed are not accessible to the patients who need them.

Help is available to patients in need through the Partnership for Prescription Assistance (PPA), a program sponsored by America's pharmaceutical research companies. To date, the PPA has helped more than 5 million patients nationwide, including more than 119,000 people in Louisiana. Since its launch in April 2005, the PPA bus tour has visited all 50 states and more than 2,000 cities. The PPA bus has been to Louisiana seven times since the program was launched.

To read the 2008 report, Medicines in Development for Mental Illnesses on the PhRMA Web site, go to: http://www.phrma.org.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address: http://phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://innovation.org

For information on the Partnership for Prescription Assistance, visit: http://pparx.org

For information on the danger of imported drugs, visit: http://buysafedrugs.info


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
2. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
3. Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
4. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
5. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
6. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
7. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
8. 92 Medicines and Vaccines now in Development for HIV/AIDS
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/11/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it will release its ... host a conference call at 9:00am ET. The Company ... results and its strategy and outlook for the remainder ... Erez Raphael , Chief Executive Officer, and Zvi ...
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 18, 2017 , ... The Brian Gifford Agency, an Indiana-based firm providing asset ... of Campagna Academy in a charity drive to provide for at-risk children and teens ... Campagna Academy is a nonprofit organization that has offered critical programs to at-risk and ...
(Date:8/18/2017)... ... 2017 , ... The Golseth Agency, a Texas based insurance management and financial ... regional charity campaign organized to provide support to Christina Upchurch and her two children ... and her children returned from out of town to find her husband passed away ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has become ... and conditions of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids ... marketing efforts with its product now available through Jet.com. , After 25 years ... effervescent powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. ...
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, the leading provider of ... today the launch of a redesigned corporate website, 800response.com . , ... design, and an enhanced search directory for businesses and advertising agencies to use ...
Breaking Medicine News(10 mins):